Could Zoetis Inc. (ZTS) Change Direction After Reaching Record High?

February 15, 2018 - By Stephen Andrade

Investors sentiment increased to 1.1 in 2017 Q3. Its up 0.06, from 1.04 in 2017Q2. It increased, as 41 investors sold Zoetis Inc. shares while 233 reduced holdings. 62 funds opened positions while 240 raised stakes. 440.74 million shares or 0.80% less from 444.27 million shares in 2017Q2 were reported.
Strs Ohio reported 445,127 shares. Tributary Capital Mgmt Limited Liability Co holds 0.26% or 46,800 shares in its portfolio. Provise Mgmt Grp Inc Lc holds 0.08% in Zoetis Inc. (NYSE:ZTS) or 8,179 shares. Paradigm Asset Management Ltd Liability Corporation reported 45,880 shares. Prelude Cap Management Ltd holds 0.08% of its portfolio in Zoetis Inc. (NYSE:ZTS) for 13,745 shares. Fort Washington Inv Advisors Incorporated Oh reported 8,145 shares. Daniel Devine Comm has invested 1.18% of its portfolio in Zoetis Inc. (NYSE:ZTS). Financial Bank Of New York Mellon Corporation has 4.96 million shares. Raymond James Advisors holds 0.01% or 36,268 shares in its portfolio. Nuveen Asset Management Limited Liability Company reported 0.01% of its portfolio in Zoetis Inc. (NYSE:ZTS). Pax Management Llc holds 1.15% or 316,754 shares. 75,000 were accumulated by Bright Rock Mngmt Llc. Retirement Of Alabama invested in 0.08% or 238,113 shares. 9,500 are held by Northeast Fin Consultants. Train Babcock Advsrs Limited Liability Com accumulated 77,915 shares.

The stock of Zoetis Inc. (NYSE:ZTS) reached all time high today, Feb, 15 and still has $84.13 target or 9.00 % above today’s $77.18 share price. This indicates more upside for the $37.61B company. This technical setup was reported by Barchart.com. If the $84.13 PT is reached, the company will be worth $3.38B more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events.

The stock increased 3.65% or $2.72 during the last trading session, reaching $77.18. About 2.51 million shares traded or 4.26% up from the average. Zoetis Inc. (NYSE:ZTS) has risen 29.89% since February 15, 2017 and is uptrending. It has outperformed by 13.19% the S&P500.

Zoetis Inc. (NYSE:ZTS) Ratings Coverage

Among 21 analysts covering Zoetis Inc (NYSE:ZTS), 16 have Buy rating, 0 Sell and 5 Hold. Therefore 76% are positive. Zoetis Inc had 70 analyst reports since July 24, 2015 according to SRatingsIntel. Cantor Fitzgerald maintained Zoetis Inc. (NYSE:ZTS) rating on Monday, August 14. Cantor Fitzgerald has “Buy” rating and $7500 target. The company was maintained on Monday, July 17 by Deutsche Bank. Craig Hallum maintained the stock with “Buy” rating in Wednesday, August 9 report. The rating was maintained by Jefferies with “Buy” on Monday, October 16. The rating was downgraded by BMO Capital Markets on Tuesday, June 13 to “Market Perform”. On Friday, September 29 the stock rating was maintained by Piper Jaffray with “Buy”. The company was maintained on Tuesday, January 16 by Stifel Nicolaus. The rating was upgraded by Cowen & Co on Thursday, December 15 to “Outperform”. The stock of Zoetis Inc. (NYSE:ZTS) has “Hold” rating given on Wednesday, July 26 by Deutsche Bank. Cantor Fitzgerald initiated Zoetis Inc. (NYSE:ZTS) on Friday, June 16 with “Overweight” rating.

More recent Zoetis Inc. (NYSE:ZTS) news were published by: Streetinsider.com which released: “Zoetis Inc. (ZTS) PT Raised to $90 at Cantor Fitzgerald on 4Q Beat; ‘Positive …” on February 15, 2018. Also Nasdaq.com published the news titled: “Zoetis (ZTS) Warming Up to Q4 Earnings: What’s in Store?” on February 09, 2018. Zacks.com‘s news article titled: “Zoetis (ZTS) Beats on Q4 Earnings & Sales, Gives 2018 View” with publication date: February 15, 2018 was also an interesting one.

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines for livestock and companion animals in the United States and internationally. The company has market cap of $37.61 billion. It offers anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; and parasiticides that prevent or eliminate external and internal parasites, such as fleas, ticks, and worms. It has a 40.64 P/E ratio. The firm also provides medicated feed additives that offer medicines to livestock; and other pharmaceutical products, including pain and sedation, oncology, antiemetic, allergy and dermatology, and reproductive products.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.